Antonio Abbate, MD
Cardiovascular Disease · Charlottesville, VANPI 1184849168
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Novo Nordisk AS at 30.5% of the total. Reporting peaked in 2024 at $68,159 and has fallen 93.6% since, to $4,384 in 2025. Among cardiovascular disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $1237.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$49K
- Kiniksa Pharmaceuticals International, PLC$40K
- Kiniksa Pharmaceuticals, Ltd.$38K
- Janssen Scientific Affairs, LLC$13K
- Novo Nordisk$7K
- Merck$7K
- plus $7K from 10 others
Across 24 payments — averaging $161,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3.7M
- Janssen Research & Development, LLC$102K
- Kiniksa Pharmaceuticals, Ltd.$10K
- Swedish Orphan Biovitrum AB$9K
- Regeneron$7K
- Novo Nordisk AS$2K
- plus $1K from 1 others
What the payments were for
- Consulting fees$77,21948%
- Speaking & faculty fees$52,93033%
- Travel & lodging$26,64417%
- Food & beverage$3,9932%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 13 | $49,101 |
| Kiniksa Pharmaceuticals International, PLC | 26 | $39,643 |
| Kiniksa Pharmaceuticals, Ltd. | 42 | $37,766 |
| Janssen Scientific Affairs, LLC | 11 | $12,875 |
| Novo Nordisk | 8 | $7,312 |
| Merck | 8 | $6,895 |
| Sanofi-aventis U.S. LLC | 1 | $3,608 |
| Daiichi Sankyo Inc. | 1 | $1,593 |
| Novartis | 10 | $1,046 |
| Sobi, Inc | 1 | $430 |
| Amgen | 2 | $155 |
| AstraZeneca | 2 | $148 |
| Abiomed | 2 | $101 |
| Sanofi | 1 | $99 |
| Vifor Pharma, Inc. | 1 | $35 |
| ZOLL Circulation Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,821 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $64,416 |
| FarxigaDapagliflozin Propanediol | 28 | $30,965 |
| EliquisApixaban | 18 | $27,976 |
| Repatha SureclickEvolocumab | 23 | $20,158 |
| Colchicine | 37 | $2,938 |
| MitigareColchicine | 12 | $2,430 |
| Eplerenone | 16 | $1,817 |
| Rosuvastatin Calcium | 83 | $1,381 |
| Metoprolol Succinate | 78 | $1,191 |
| Spironolactone | 51 | $595 |
| Ezetimibe | 27 | $516 |
| Losartan Potassium | 51 | $429 |
| Amlodipine Besylate | 36 | $258 |
| Pantoprazole Sodium | 14 | $164 |
| ClopidogrelClopidogrel Bisulfate | 22 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $148 | $30,96528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Charlottesville
- Michael AyersCharlottesville$305K
- David LimCharlottesville$264K
- Jamieson BourqueCharlottesville$104K
- Christopher KramerCharlottesville$103K
- Todd VillinesCharlottesville$70K
- Jonathan LindnerCharlottesville$57K
- Aditya SharmaCharlottesville$41K
- Amit PatelCharlottesville$22K
- George VetrovecRichmond$2.3M
- Hamid TaheriManassas$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.